Overview

DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

Status:
Active, not recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving chemoradiation treatment for the treatment of head and neck cancer
Phase:
Phase 3
Details
Lead Sponsor:
Soligenix